119 related articles for article (PubMed ID: 7309287)
1. Development of resistance to vincristine in a childhood rhabdomyosarcoma growing in immune-deprived mice.
Houghton JA; Houghton PJ; Brodeur GM; Green AA
Int J Cancer; 1981 Oct; 28(4):409-15. PubMed ID: 7309287
[TBL] [Abstract][Full Text] [Related]
2. In situ selection of a human rhabdomyosarcoma resistant to vincristine with altered beta-tubulins.
Houghton JA; Houghton PJ; Hazelton BJ; Douglass EC
Cancer Res; 1985 Jun; 45(6):2706-12. PubMed ID: 3986804
[TBL] [Abstract][Full Text] [Related]
3. Reciprocal cross-resistance in human rhabdomyosarcomas selected in vivo for primary resistance to vincristine and L-phenylalanine mustard.
Horton JK; Houghton PJ; Houghton JA
Cancer Res; 1987 Dec; 47(23):6288-93. PubMed ID: 2890432
[TBL] [Abstract][Full Text] [Related]
4. Determinants of intrinsic sensitivity to Vinca alkaloids in xenografts of pediatric rhabdomyosarcomas.
Houghton JA; Williams LG; Torrance PM; Houghton PJ
Cancer Res; 1984 Feb; 44(2):582-90. PubMed ID: 6692363
[TBL] [Abstract][Full Text] [Related]
5. Relationships between tumor responsiveness, vincristine pharmacokinetics and arrest of mitosis in human tumor xenografts.
Horton JK; Houghton PJ; Houghton JA
Biochem Pharmacol; 1988 Oct; 37(20):3995-4000. PubMed ID: 3190743
[TBL] [Abstract][Full Text] [Related]
6. Up-regulation of GLI1 in vincristine-resistant rhabdomyosarcoma and Ewing sarcoma.
Yoon JW; Lamm M; Chandler C; Iannaccone P; Walterhouse D
BMC Cancer; 2020 Jun; 20(1):511. PubMed ID: 32493277
[TBL] [Abstract][Full Text] [Related]
7. Ascorbic acid increases drug accumulation and reverses vincristine resistance of human non-small-cell lung-cancer cells.
Chiang CD; Song EJ; Yang VC; Chao CC
Biochem J; 1994 Aug; 301 ( Pt 3)(Pt 3):759-64. PubMed ID: 7914401
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a melphalan-resistant rhabdomyosarcoma xenograft with cross-resistance to vincristine and enhanced sensitivity following buthionine sulfoximine-mediated glutathione depletion.
Rosenberg MC; Colvin OM; Griffith OW; Bigner SH; Elion GB; Horton JK; Lilley E; Bigner DD; Friedman HS
Cancer Res; 1989 Dec; 49(24 Pt 1):6917-22. PubMed ID: 2582434
[TBL] [Abstract][Full Text] [Related]
9. Childhood rhabdomyosarcoma xenografts: responses to DNA-interacting agents and agents used in current clinical therapy.
Houghton JA; Cook RL; Lutz PJ; Houghton PJ
Eur J Cancer Clin Oncol; 1984 Jul; 20(7):955-60. PubMed ID: 6430707
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin.
Houghton PJ; Cheshire PJ; Hallman JC; Bissery MC; Mathieu-Boué A; Houghton JA
Cancer Res; 1993 Jun; 53(12):2823-9. PubMed ID: 8504425
[TBL] [Abstract][Full Text] [Related]
11. Occurrence of a multidrug-resistant phenotype in human lung xenografts.
Mattern J; Bak M; Volm M
Br J Cancer; 1987 Oct; 56(4):407-11. PubMed ID: 3689658
[TBL] [Abstract][Full Text] [Related]
12. Reversal of Vinca alkaloid resistance by anti-P-glycoprotein monoclonal antibody HYB-241 in a human tumor xenograft.
Rittmann-Grauer LS; Yong MA; Sanders V; Mackensen DG
Cancer Res; 1992 Apr; 52(7):1810-6. PubMed ID: 1348013
[TBL] [Abstract][Full Text] [Related]
13. Intrinsic and acquired multidrug resistance in human lung carcinomas grown in nude mice.
Mattern J; Bak M; Volm M
Anticancer Res; 1990; 10(1):177-80. PubMed ID: 1970715
[TBL] [Abstract][Full Text] [Related]
14. Establishment of Vincristine-resistant and vindesine-resistant lines of murine lymphoblasts in vitro and characterisation of their patterns of cross-resistance and drug sensitivities.
Hill BT; Whelan RD
Cancer Chemother Pharmacol; 1982; 8(2):163-9. PubMed ID: 7105380
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of a novel bis-naphthalimide anticancer agent, DMP 840, against human xenografts derived from adult, juvenile, and pediatric cancers.
Houghton PJ; Cheshire PJ; Hallman JC; Gross JL; McRipley RJ; Sun JH; Behrens CH; Dexter DL; Houghton JA
Cancer Chemother Pharmacol; 1994; 33(4):265-72. PubMed ID: 8281618
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy of childhood rhabdomyosarcomas growing as xenografts in immune-deprived mice.
Houghton JA; Houghton PJ; Green AA
Cancer Res; 1982 Feb; 42(2):535-9. PubMed ID: 7034923
[TBL] [Abstract][Full Text] [Related]
17. Promotion by verapamil of vincristine responsiveness in tumor cell lines inherently resistant to the drug.
Tsuruo T; Iida H; Naganuma K; Tsukagoshi S; Sakurai Y
Cancer Res; 1983 Feb; 43(2):808-13. PubMed ID: 6848194
[TBL] [Abstract][Full Text] [Related]
18. Modulation by verapamil of vincristine pharmacokinetics and toxicity in mice bearing human tumor xenografts.
Horton JK; Thimmaiah KN; Houghton JA; Horowitz ME; Houghton PJ
Biochem Pharmacol; 1989 Jun; 38(11):1727-36. PubMed ID: 2735930
[TBL] [Abstract][Full Text] [Related]
19. Relationship between binding affinity, retention and sensitivity of human rhabdomyosarcoma xenografts to Vinca alkaloids.
Houghton JA; Williams LG; Dodge RK; George SL; Hazelton BJ; Houghton PJ
Biochem Pharmacol; 1987 Jan; 36(1):81-8. PubMed ID: 3541941
[TBL] [Abstract][Full Text] [Related]
20. The influence of recombinant human insulin-like growth factor-I (rhIGF-I) on cell growth and cytotoxicity of drugs in childhood rhabdomyosarcoma cell lines and xenograft models.
Gidding CE; Germain GS; Dilling MB; Meeuwsen-de Boer TG; Ashmun RA; de Graaf SS; Veverka KA; Kamps WA; Houghton PJ
Cancer Chemother Pharmacol; 2000; 45(1):21-30. PubMed ID: 10647497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
